A Tibet Haisco Pharmaceutical Co. Ltd. patent describes new phosphodiesterase PDE4B inhibitors potentially useful for the treatment of cancer, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
Max Biopharma Inc. and Metaba LLC are collaborating to study the effects of oxysterol drug candidates that target metabolic dysfunction-associated steatohepatitis (MASH, formerly nonalcoholic steatohepatitis or NASH), idiopathic pulmonary fibrosis, chronic inflammation, and atherosclerosis on metabolic processes.
Researchers from the Peking University Health Science Center have developed a murine model of RSV infection based on the knockout of the Rag2 gene using CRISPR/Cas9 (Rag2-/- mice).
On the verge of top-line data from its phase IIb trial with oral small-molecule CC chemokine receptor 4 (CCR4) antagonist zelnecirnon in atopic dermatitis (AD), due around the middle of this year, Rapt Therapeutics Inc. said the U.S. FDA has imposed a clinical hold on that study with the otherwise promising drug, also known as RPT-193, in AD as well as the phase IIa trial with the same compound in asthma.
Chiesi Farmaceutici SpA has detailed new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis (IPF).
Intellia Therapeutics Inc. and Recode Therapeutics Inc. have established a strategic collaboration to develop novel genomic medicines for the treatment of cystic fibrosis.